Diseases

South Africa's High Court has kept the semaglutide compounding ban in place, dismissing iDexis's appeal as an 'abuse of process' while SAHPRA and SAPC finish their investigations. #SyenzaNews #MarketAccess #Pharma

Enhertu's DESTINY-Lung04 trial cut the risk of progression versus chemo-immunotherapy in first-line HER2-mutant NSCLC, but an immature overall-survival trend and a 20.8% ILD rate complicate the path to a first-line label. #SyenzaNews #Oncology #NSCLC #MarketAccess

Every NCCN academic cancer center now reports a shortage of at least one anticancer medicine, led by ifosfamide (94%) and carboplatin (71%). Pharmacy directors say three years of policy have not moved the problem. #SyenzaNews #DrugShortages #Oncology #MarketAccess

NICE has opened consultation on draft guidance that does not recommend lenacapavir for HIV PrEP, finding the six-monthly injection is not value for money for the NHS in England. #SyenzaNews #HTA #HIV #PrEP #MarketAccess

Real-world UK data presented at ERS 2026 link semaglutide to fewer asthma attacks and COPD exacerbations. The indication stays metabolic, but the signal raises a real question for value and access teams. #SyenzaNews #MarketAccess #GLP1 #Respiratory

Camizestrant (Etcamah) gains accelerated FDA approval for ESR1-mutated advanced breast cancer, with median progression-free survival of 16 months versus 9.2 months in SERENA-6. #SyenzaNews #BreastCancer #FDA #Oncology

South Africa has initiated 55,123 people on twice-yearly lenacapavir PrEP in the programme's first 94 days. Demand is strongest in Gauteng and KwaZulu-Natal; branded supply, second-dose retention and the 2027 generic tender are the real constraints. #SyenzaNews #HIVPrevention #Lenacapavir #MarketAccess

Novartis and The Max Foundation mark 25 years of partnership that has delivered cancer treatment to more than 100,000 patients across 71 LMICs. The next test is whether the model can carry a broader oncology portfolio and transition to country funding. #SyenzaNews #MarketAccess #GlobalHealth

An Insilico Medicine phase 2a trial found six proteomic aging clocks all detected lower biological age in patients treated with rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis. #SyenzaNews #Proteomics #AgingClocks #DrugDiscovery #IPF

Novo Nordisk has stopped the two remaining ziltivekimab heart failure trials after a futility review, leaving ARTEMIS as the last anti-inflammatory cardiovascular outcomes bet. #SyenzaNews #MarketAccess #Cardiology #HTA

Aspen Pharmacare has walked away from local lenacapavir manufacturing over the lack of guaranteed volumes, and is instead backing Merck's once-monthly oral PrEP pill, alimatravir. #SyenzaNews #HIV #PrEP #MarketAccess

Aspen Pharmacare posted 22% normalised earnings growth and is betting on a manufacturing rebound and a generic semaglutide rollout for FY2027. #SyenzaNews #Pharma #GLP1 #MarketAccess #SouthAfrica